Ellin-Kristina Hillert
Overview
Explore the profile of Ellin-Kristina Hillert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Selvaraju K, Mofers A, Pellegrini P, Salomonsson J, Ahlner A, Morad V, et al.
Sci Rep
. 2019 Nov;
9(1):17501.
PMID: 31745183
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
2.
Selvaraju K, Mofers A, Pellegrini P, Salomonsson J, Ahlner A, Morad V, et al.
Sci Rep
. 2019 Jul;
9(1):9841.
PMID: 31285509
A large number of natural products have been advocated as anticancer agents. Many of these compounds contain functional groups characterized by chemical reactivity. It is not clear whether distinct mechanisms...
3.
Hillert E, Brnjic S, Zhang X, Mazurkiewicz M, Saei A, Mofers A, et al.
Cancer Lett
. 2019 Feb;
448:70-83.
PMID: 30768956
Proteasome inhibitors have been shown to induce cell death in cancer cells by triggering an acute proteotoxic stress response characterized by accumulation of poly-ubiquitinated proteins, ER stress and the production...
4.
Zhang X, Pellegrini P, Saei A, Hillert E, Mazurkiewicz M, Olofsson M, et al.
Biochem Pharmacol
. 2018 Aug;
156:291-301.
PMID: 30149015
Human cancers are characterized by intrinsic or acquired resistance to apoptosis and evasion of apoptosis has been proposed to contribute to treatment resistance. Bis-benzylidine piperidone compounds, containing α,β-unsaturated carbonyl functionalities,...
5.
Mazurkiewicz M, Hillert E, Wang X, Pellegrini P, Olofsson M, Selvaraju K, et al.
Oncotarget
. 2017 Apr;
8(13):21115-21127.
PMID: 28423502
The non-genotoxic nature of proteasome inhibition makes it an attractive therapeutic option for the treatment of pediatric malignancies. We recently described the small molecule VLX1570 as an inhibitor of proteasome...
6.
MacLeod R, Hillert E, Cameron R, Baillie G
Future Sci OA
. 2016 Dec;
1(3):FSO11.
PMID: 28031886
Alzheimer's disease (AD) is the most common form of dementia in the elderly and its prevalence is set to increase rapidly in coming decades. However, there are as yet no...
7.
Wang X, Mazurkiewicz M, Hillert E, Olofsson M, Pierrou S, Hillertz P, et al.
Sci Rep
. 2016 Jul;
6:30667.
PMID: 27472448
No abstract available.
8.
Wang X, Mazurkiewicz M, Hillert E, Olofsson M, Pierrou S, Hillertz P, et al.
Sci Rep
. 2016 Jun;
6:26979.
PMID: 27264969
Inhibition of deubiquitinase (DUB) activity is a promising strategy for cancer therapy. VLX1570 is an inhibitor of proteasome DUB activity currently in clinical trials for relapsed multiple myeloma. Here we...
9.
Min X, Ungureanu D, Maxwell S, Hammaren H, Thibault S, Hillert E, et al.
J Biol Chem
. 2015 Sep;
290(45):27261-27270.
PMID: 26359499
JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling through cytokine receptors involved in immune responses and inflammation. JAKs are characterized by dual kinase...
10.
Eisenach C, Papanatsiou M, Hillert E, Blatt M
Plant J
. 2014 Feb;
78(2):203-14.
PMID: 24517091
GORK is the only outward-rectifying Kv-like K(+) channel expressed in guard cells. Its activity is tightly regulated to facilitate K(+) efflux for stomatal closure and is elevated in ABA in...